Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares

Hyo Jin Choi, Chan Hee Lee, Joo Hyun Lee, Bo Young Yoon, Hyoun Ah Kim, Chang Hee Suh, Sang Tae Choi, Jung Soo Song, Ho Yeon Joo, Sungjae Choi, Ji Soo Lee, Kee Chul Shin, Han Joo Baek

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it ≥ 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the ≥ 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.

Original languageEnglish
Pages (from-to)497-503
Number of pages7
JournalInternational Journal of Rheumatic Diseases
Volume20
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Republic of Korea
Gout
Uric Acid
Therapeutics
Serum
Allopurinol
Colchicine
Rheumatology
Demography

Keywords

  • flare
  • gout treatment
  • prophylactic duration
  • serum uric acid

ASJC Scopus subject areas

  • Rheumatology

Cite this

Current gout treatment and flare in South Korea : Prophylactic duration associated with fewer gout flares. / Choi, Hyo Jin; Lee, Chan Hee; Lee, Joo Hyun; Yoon, Bo Young; Kim, Hyoun Ah; Suh, Chang Hee; Choi, Sang Tae; Song, Jung Soo; Joo, Ho Yeon; Choi, Sungjae; Lee, Ji Soo; Shin, Kee Chul; Baek, Han Joo.

In: International Journal of Rheumatic Diseases, Vol. 20, No. 4, 01.04.2017, p. 497-503.

Research output: Contribution to journalArticle

Choi, HJ, Lee, CH, Lee, JH, Yoon, BY, Kim, HA, Suh, CH, Choi, ST, Song, JS, Joo, HY, Choi, S, Lee, JS, Shin, KC & Baek, HJ 2017, 'Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares', International Journal of Rheumatic Diseases, vol. 20, no. 4, pp. 497-503. https://doi.org/10.1111/1756-185X.12422
Choi, Hyo Jin ; Lee, Chan Hee ; Lee, Joo Hyun ; Yoon, Bo Young ; Kim, Hyoun Ah ; Suh, Chang Hee ; Choi, Sang Tae ; Song, Jung Soo ; Joo, Ho Yeon ; Choi, Sungjae ; Lee, Ji Soo ; Shin, Kee Chul ; Baek, Han Joo. / Current gout treatment and flare in South Korea : Prophylactic duration associated with fewer gout flares. In: International Journal of Rheumatic Diseases. 2017 ; Vol. 20, No. 4. pp. 497-503.
@article{dd74e8c9f80c4de99c79bc622a4b4573,
title = "Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares",
abstract = "Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8{\%}. Colchicine (62.3{\%}) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4{\%}) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6{\%}) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it ≥ 6 months (42.9{\%} vs. 26.3{\%}, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the ≥ 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.",
keywords = "flare, gout treatment, prophylactic duration, serum uric acid",
author = "Choi, {Hyo Jin} and Lee, {Chan Hee} and Lee, {Joo Hyun} and Yoon, {Bo Young} and Kim, {Hyoun Ah} and Suh, {Chang Hee} and Choi, {Sang Tae} and Song, {Jung Soo} and Joo, {Ho Yeon} and Sungjae Choi and Lee, {Ji Soo} and Shin, {Kee Chul} and Baek, {Han Joo}",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/1756-185X.12422",
language = "English",
volume = "20",
pages = "497--503",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Current gout treatment and flare in South Korea

T2 - Prophylactic duration associated with fewer gout flares

AU - Choi, Hyo Jin

AU - Lee, Chan Hee

AU - Lee, Joo Hyun

AU - Yoon, Bo Young

AU - Kim, Hyoun Ah

AU - Suh, Chang Hee

AU - Choi, Sang Tae

AU - Song, Jung Soo

AU - Joo, Ho Yeon

AU - Choi, Sungjae

AU - Lee, Ji Soo

AU - Shin, Kee Chul

AU - Baek, Han Joo

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it ≥ 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the ≥ 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.

AB - Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it ≥ 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the ≥ 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.

KW - flare

KW - gout treatment

KW - prophylactic duration

KW - serum uric acid

UR - http://www.scopus.com/inward/record.url?scp=85028281849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028281849&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12422

DO - 10.1111/1756-185X.12422

M3 - Article

C2 - 25160939

AN - SCOPUS:85028281849

VL - 20

SP - 497

EP - 503

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 4

ER -